Characteristic | Group 1 (N = 300) | Group 2 (N = 306) | Group 3 (N = 331) |
---|---|---|---|
Age (in years) | 68 (58–75) | 67 (58–73) | 68 (59–74) |
Sex | Â | Â | Â |
 Male | 157 (52%) | 163 (53%) | 189 (57%) |
 Female | 143 (48%) | 143 (47%) | 142 (43%) |
Tumor type | Â | Â | Â |
 Lung cancer | 108 (36%) | 108 (35%) | 113 (34%) |
 Stomach cancer | 21 (7%) | 22 (7%) | 23 (7%) |
 Colorectal cancer | 79 (26%) | 73 (24%) | 80 (24%) |
 Breast cancer | 37 (12%) | 35 (11%) | 44 (13%) |
 Other solid tumors | 55 (18%) | 68 (22%) | 71 (21%) |
Stage at diagnosis | Â | Â | Â |
 I | 12 (4%) | 19 (6%) | 18 (5%) |
 II | 23 (8%) | 17 (6%) | 34 (10%) |
 III | 63 (21%) | 64 (21%) | 65 (20%) |
 IV | 200 (67%) | 204 (67%) | 206 (62%) |
 Unknown | 2 (1%) | 2 (1%) | 8 (2%) |
Site of metastasis or recurrencea | Â | Â | Â |
 None | 26 (9%) | 22 (7%) | 35 (11%) |
 Liver | 60 (20%) | 72 (24%) | 79 (24%) |
 Lung | 110 (37%) | 95 (31%) | 91 (27%) |
 Bone | 48 (16%) | 54 (18%) | 67 (20%) |
 Brain | 34 (11%) | 35 (11%) | 31 (9%) |
 Lymph nodes | 124 (41%) | 129 (42%) | 120 (36%) |
 Others | 69 (23%) | 73 (24%) | 90 (27%) |
History of surgery | Â | Â | Â |
 Yes | 159 (53%) | 152 (50%) | 186 (56%) |
 No | 141 (47%) | 154 (50%) | 144 (44%) |
 Unknown | 0 (0%) | 0 (0%) | 1 (0%) |
Hospitalization | Â | Â | Â |
 Yes | 60 (20%) | 71 (23%) | 64 (19%) |
 No | 240 (80%) | 235 (77%) | 267 (81%) |
ECOG performance status | Â | Â | Â |
 0 | 156 (52%) | 148 (48%) | 160 (48%) |
 1 | 115 (38%) | 127 (42%) | 143 (43%) |
 2 | 21 (7%) | 21 (7%) | 25 (8%) |
 3 | 7 (2%) | 10 (3%) | 3 (1%) |
 Unknown (0, 1, 2, or 3) | 1 (0%) | 0 (0%) | 0 (0%) |
Type of treatmenta | Â | Â | Â |
 Chemotherapy | 186 (62%) | 195 (64%) | 225 (68%) |
 Endocrine therapy | 20 (7%) | 22 (7%) | 25 (8%) |
 Molecular targeted therapy | 56 (19%) | 49 (16%) | 58 (18%) |
 Immunotherapy | 38 (13%) | 43 (14%) | 31 (9%) |
 Palliative therapy | 17 (6%) | 10 (3%) | 10 (3%) |
 Others | 3 (1%) | 2 (1%) | 3 (1%) |
Adverse event at enrollment | Â | Â | Â |
 Yes | 186 (62%) | 200 (65%) | 220 (66%) |
 No | 113 (38%) | 106 (35%) | 110 (33%) |
 Unknown | 1 (0%) | 0 (0%) | 1 (0%) |